Insmed (Insmed) Short-Term Debt & Capital Lease Obligation : $10.6 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Insmed Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Insmed's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.6 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Insmed's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,193.4 Mil.

Insmed Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Insmed's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Short-Term Debt & Capital Lease Obligation Chart

Insmed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

12.26

12.56

10.14

8.13

10.64

Insmed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															8.13	8.98	6.60	8.95	10.64

Insmed Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Insmed Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Insmed's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Insmed (Insmed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (NAS:INSM) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

INSM:Mexico IM8N:Germany

Address

700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website

https://www.insmed.com

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Executives

Flammer Martina M.d.	officer: Chief Medical Officer	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Roger Adsett	officer: Chief Commercial Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
John Drayton Wise	officer: Chief Commercial Officer	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Michael Alexander Smith	officer: General Counsel, Senior VP	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
William Lewis	officer: President & CEO	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Schaeffer Orlov S Nicole	officer: Chief People Strategy Officer	INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Sara Bonstein	officer: Chief Financial Officer	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Melvin Md Sharoky	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Leo Lee	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Steinar J Engelsen	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
John Soriano	officer: Chief Compliance Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Christine A Pellizzari	officer: General Counsel & Secretary	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Alfred Altomari	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807